Novartis initiates Phase III trial of Atrasentan in pediatric IgAN patients
Novartis is conducting Phase III trial to evaluate the efficacy and safety of Atrasentan in pediatric patients with primary IgAN.
Asset / Drug
Drug and asset intelligence for Atrasentan with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.